Ad
related to: astrazeneca lung cancer products- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Lung Cancer Screening
Learn About Lung Cancer Screening.
Is This the Right Test for You?
- Lung Cancer Treatment
Free Lung Cancer Treatment Guide.
Find Lung Cancer Treatment Options.
- Lung Cancer Signs
Free Lung Cancer Treatment Guide.
Lung Cancer Signs and Symptoms.
- Need a Second Opinion?
Search results
Results from the WOW.Com Content Network
AstraZeneca said Imfinzi was also recently granted Breakthrough Therapy Designation by the FDA in the same setting, which will help accelerate the regulatory review. Small cell lung cancer is a ...
By Eva Mathews (Reuters) -AstraZeneca said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung cancer, making it the ...
(Reuters) - The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.
At the World Conference on Lung Cancer (WCLC), the British pharma giant shared results from the NeoCOAST-2 Phase 2 platform trial of Imfinzi (durvalumab) in multiple combinations, before and after ...
Durvalumab, [8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. [9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1 (CD279).
It is being investigated for the treatment of cancer by AstraZeneca. [1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. [2] It has been given conditional approval for these indication in China. [3]
AstraZeneca said that additional data from the Phase 3 trial of its Imfinzi treatment showed “unprecedented” survival in unresectable, Stage 3 cell lung cancer with an estimated 50% of ...
On February 27, 2008, AstraZeneca announced that the use of cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On 8 March 2010, AstraZeneca issued a press-release stating that cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was ...
Ad
related to: astrazeneca lung cancer products